Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

675 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S, Soejima K, Yasuda H, Naoki K, Kawada I, Watanabe H, Nakachi I, Satomi R, Nakayama S, Ikemura S, Terai H, Sato T, Morosawa M, Asano K. Yoda S, et al. Among authors: soejima k. Cancer Chemother Pharmacol. 2011 Mar;67(3):717-22. doi: 10.1007/s00280-010-1539-y. Epub 2010 Dec 9. Cancer Chemother Pharmacol. 2011. PMID: 21152917 Clinical Trial.
A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.
Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K. Ikemura S, et al. Among authors: soejima k. Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22. Jpn J Clin Oncol. 2015. PMID: 25612761 Clinical Trial.
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer.
Ishioka K, Yasuda H, Hamamoto J, Terai H, Emoto K, Kim TJ, Hirose S, Kamatani T, Mimaki S, Arai D, Ohgino K, Tani T, Masuzawa K, Manabe T, Shinozaki T, Mitsuishi A, Ebisudani T, Fukushima T, Ozaki M, Ikemura S, Kawada I, Naoki K, Nakamura M, Ohtsuka T, Asamura H, Tsuchihara K, Hayashi Y, Hegab AE, Kobayashi SS, Kohno T, Watanabe H, Ornitz DM, Betsuyaku T, Soejima K, Fukunaga K. Ishioka K, et al. Among authors: soejima k. Cancer Res. 2021 Jul 15;81(14):3916-3929. doi: 10.1158/0008-5472.CAN-20-4048. Epub 2021 Jun 3. Cancer Res. 2021. PMID: 34083250
Clinical Characteristics and Therapeutic Outcomes of Metastatic Peritoneal Carcinomatosis in Non-Small-Cell Lung Cancer.
Tani T, Nakachi I, Ikemura S, Nukaga S, Ohgino K, Kuroda A, Terai H, Masuzawa K, Shinozaki T, Ishioka K, Funatsu Y, Koh H, Fukunaga K, Soejima K; Keio Lung Oncology Group (KLOG). Tani T, et al. Among authors: soejima k. Cancer Manag Res. 2021 Sep 29;13:7497-7503. doi: 10.2147/CMAR.S330103. eCollection 2021. Cancer Manag Res. 2021. PMID: 34616179 Free PMC article.
Real-world clinical practice for advanced non-small-cell lung cancer in the very elderly: A retrospective multicenter analysis.
Fukushima T, Oyamada Y, Ikemura S, Nukaga S, Inoue T, Arai D, Ohgino K, Kuroda A, Ishioka K, Sakamaki F, Suzuki Y, Terai H, Yasuda H, Kawada I, Fukunaga K, Soejima K. Fukushima T, et al. Among authors: soejima k. Clin Lung Cancer. 2022 Sep;23(6):532-541. doi: 10.1016/j.cllc.2022.05.003. Epub 2022 May 11. Clin Lung Cancer. 2022. PMID: 35680551 Free article.
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. Nakachi I, et al. Among authors: soejima k. Mol Cancer Res. 2010 Aug;8(8):1142-51. doi: 10.1158/1541-7786.MCR-09-0388. Epub 2010 Jul 20. Mol Cancer Res. 2010. PMID: 20647329
675 results